StockNews.AI
A
StockNews.AI
3 days

Agilent MMR IHC Panel pharmDx (Dako Omnis) Receives FDA Approval as a Companion Diagnostic Test for Colorectal Cancer

1. Agilent's MMR IHC Panel received FDA approval for colorectal cancer diagnostics. 2. This enables personalized treatment options linked to specific cancer patient profiles.

FDA Approval
-1.91%Current Return
VS
-0.6%S&P 500
$120.1108/20 08:14 AM EDTEvent Start
$117.8108/21 02:54 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

FDA approval enhances Agilent's product portfolio and market position. Similar approvals have historically boosted stock prices in diagnostics.

How important is it?

FDA approval often correlates with significant stock price impacts in biotech.

Why Short Term?

FDA approval can lead to immediate revenue increases from breast cancer testing. Recent examples show rapid stock price corrections following such positive news.

Related Companies

BMYDHRILMN
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion diagnostic (CDx) test for colorectal cancer. This test aids in identifying mismatch repair deficient (dMMR) colorectal cancer (CRC) patients who are eligible for treatment with Bristol Myers Squibb's Opdivo® (nivolumab) alone or Opdivo (nivolumab) in combination with Yervoy® (ipilimumab). The MMR IHC Panel pharmDx (Dako Om.

Related News